<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="healthcare" lang="en"><front><journal-meta><journal-id journal-id-type="publisher">IJCRR</journal-id><journal-id journal-id-type="nlm-ta">I Journ Cur Res Re</journal-id><journal-title-group><journal-title>International Journal of Current Research and Review</journal-title><abbrev-journal-title abbrev-type="pubmed">I Journ Cur Res Re</abbrev-journal-title></journal-title-group><issn pub-type="ppub">2231-2196</issn><issn pub-type="opub">0975-5241</issn><publisher><publisher-name>Radiance Research Academy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">3804</article-id><article-id pub-id-type="doi"/><article-id pub-id-type="doi-url"> http://dx.doi.org/10.31782/IJCRR.2021.SP221</article-id><article-categories><subj-group subj-group-type="heading"><subject>Healthcare</subject></subj-group></article-categories><title-group><article-title>Inconclusive in COVID-19 Reverse Transcriptase-Polymerase Chain Reaction Test: A Diagnostic Dilemma&#13;
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Subhendu</surname><given-names>Sikdar</given-names></name></contrib><contrib contrib-type="author"><name><surname>Somnath</surname><given-names>Bhunia</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Majumdar Amit</given-names></name></contrib><contrib contrib-type="author"><name><surname>Soma</surname><given-names>Sarkar</given-names></name></contrib><contrib contrib-type="author"><name><surname>Swagata</surname><given-names>Ganguly Bhattacharjee</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><day>11</day><month>06</month><year>2021</year></pub-date><volume>Wa</volume><issue>OV</issue><fpage>105</fpage><lpage>108</lpage><permissions><copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p></license></permissions><abstract><p>Introduction: Cases of COVID 19 pandemic in India has been reported since 30th January 2020. Cases are detected by RTqPCR targeting one or more gene (E/S/N/RdRp/ORF1) based on ICMR guidelines. Results are to be reported as __ampersandsignlsquo;Inconclusive__ampersandsignrsquo; if only one target gene is detected in multiplex qPCR. Objective: The present study is aimed to analyze the __ampersandsignldquo;Inconclusive__ampersandsignrdquo; results based on the Ct value of the detected target gene, duration of symptoms of cases and by repeat testing with another fresh sample after 3 days. Methods: This cross-sectional observational study was conducted from June 2020 to December 2020 in a tertiary care hospital in Kolkata. Nasopharyngeal and throat swab from suspected cases were collected and sent to our laboratory for RT-qPCR. Results: A total of 94,443 samples were tested in our laboratory for seven months. 8,455 (8.95%) samples were found to be inconclusive. Out of them, 1287 (15.22%) cases became positive and 3858 (45.63%) became negative after retesting with another fresh sample after 3 days. 1540 (18.21%) cases were lost for follow up. All inconclusive results were correlated with Ct value and duration of the disease symptoms. Maximum cases (64.96%) with Ct value 36 became negative on retesting. Most of the cases (28.36%) had symptoms of less than 2 days duration, among positive cases, whereas, 36.86% cases had symptoms of more than 12 days duration among negative cases. 1770 (20.94%) samples were found to be inconclusive again on retesting after 3 days. Most of these cases (46.55%) had a Ct value within 34- 36 on the first test. Conclusion: All inconclusive samples should always be subjected to further testing after 3 days. There is a chance to get positive results from inconclusive cases whose Ct value is less than 34. Quality control and quality assurance of all processes should be done to check any pre-analytical or analytical fallacies. Clinicians and patients both are to be educated about the probable reasons of inconclusive also&#13;
</p></abstract><kwd-group><kwd>COVID 19</kwd><kwd> Ct value</kwd><kwd> Inconclusive</kwd><kwd> RT-PCR</kwd><kwd> Target gene</kwd><kwd> Retesting</kwd></kwd-group></article-meta></front></article>
